Emergent BioSolutions
400 Professional Drive
Suite 400
Gaithersburg
Maryland
20879
United States
Tel: 240-631-3200
Fax: 240-631-3203
About Emergent BioSolutions
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter.
Stock Symbol: EBS
545 articles with Emergent BioSolutions
-
Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19
4/2/2021
Emergent BioSolutions Inc. (NYSE:EBS) today provided an update on the evaluation of its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) for the treatment of hospitalized patients with COVID-19. The Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) trial, also known as INSIGHT-013, sponsored and supported by the National Institute of Allergy and Infectious Diseases (NIAID)
-
Emergent BioSolutions to Participate in Investor Conferences - Mar 01, 2021
3/1/2021
Emergent BioSolutions Inc. announced that members of the company’s senior management team will participate in the following investor conferences:.
-
Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020
2/18/2021
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2020.
-
Emergent BioSolutions to Release Fourth Quarter and Full Year 2020 Financial Results and Conduct a Conference Call on February 18, 2021
2/4/2021
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 18, 2021 at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2020, recent business developments, financial outlook for full year 2021, and revenue guidance for the first quarter of 2021.
-
Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™
1/25/2021
Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, Inc. (NASDAQ:HGEN) (Humanigen) today announced that they have entered into a contract development and manufacturing (CDMO) services agreement to accelerate the drug product manufacturing of lenzilumab
-
Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results
1/10/2021
Expects continued strong financial and operating momentum in 2021, forecasting total revenues of $2 billion at the midpoint and Adjusted EBITDA of $780 million at the midpoint, both increases year-over-year
-
Emergent BioSolutions to Participate in Investor Conferences - Jan 04, 2021
1/4/2021
Emergent BioSolutions Inc. announced that members of the company’s executive management team will participate in the following investor conferences in the first quarter of 2021
-
Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2020 and Updates Full Year 2020 Guidance
11/5/2020
Emergent BioSolutions Inc. reported financial results for the three and nine months ended September 30, 2020 and updated its full year 2020 guidance.
-
Emergent BioSolutions to Release Third Quarter 2020 Financial Results and Conduct Conference Call on November 5, 2020
10/15/2020
Emergent BioSolutions Inc. will host a conference call on Thursday, November 5, 2020 at 5:00 pm to discuss the financial results for the third quarter of 2020, recent business developments, revenue guidance for the fourth quarter of 2020, and financial outlook for full year 2020.
-
Clinical Catch-Up: October 5-9
10/12/2020
It was a moderately busy week for clinical trial news. Here’s a look. -
Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19
10/8/2020
NIAID has initiated a Phase 3 clinical trial to evaluate the safety, tolerability, and efficacy of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), as a potential treatment in adult patients hospitalized with COVID-19 Emergent is planning additional clinical trials to evaluate COVID-HIG for potential use in other patient populations or individuals at high risk of exposure GAITHERSBURG, Md., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolution
-
Emergent BioSolutions Teams Up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to Highlight Importance of Overdose Reversal Medicines on International Overdose Awareness Day
8/31/2020
Organizations Join Together to Raise Awareness of Overdose Reversal Medicines During August 31st Games
-
Emergent BioSolutions Announces Appointment of Marvin White to the Company’s Board of Directors
8/26/2020
Emergent BioSolutions Inc. announced that the company’s board of directors appointed Marvin L. White as a Class II director to serve on the board effective October 1, 2020, with an initial term expiring at the 2023 annual meeting of stockholders.
-
Emergent BioSolutions to Participate in Virtual Investor Conferences - Aug 18, 2020
8/18/2020
Emergent BioSolutions Inc. announced that members of the company’s executive management team will participate in the following virtual investor conferences through the end of September 2020
-
Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months
8/17/2020
Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration has approved the extension of the shelf life of NARCAN® Nasal Spray from 24 months to 36 months.
-
Emergent BioSolutions Announces Successful Completion of Offering of 3.875% Senior Unsecured Notes Due 2028
8/7/2020
Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has completed its previously announced offering of $450 million in aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028 (the “Notes”). The Notes are fully and unconditionally guaranteed on a senior unsecured basis by all of the Company’s direct and indirect subsidiaries that guarantee debt under its credit facilities. The Company has used the
-
Emergent BioSolutions Announces Upsize and Pricing of $450 Million of 3.875% Senior Unsecured Notes Due 2028
8/4/2020
Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has priced its offering of $450 million aggregate principal amount of 3.875% Senior Unsecured Notes due 2028 (the “Notes”), representing an increase of $50 million in aggregate principal amount from the initially proposed offering size.
-
Emergent BioSolutions Announces Proposed Offering of $400 Million of Senior Unsecured Notes
8/4/2020
Emergent BioSolutions Inc. announced that it intends to offer $400 million aggregate principal amount of senior unsecured notes with an expected maturity date of August 2028.
-
Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2020 and Revises Upward Full Year 2020 Guidance
7/30/2020
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the three and six months ended June 30, 2020 and revised upward full year 2020 guidance.
-
Gaithersburg, Maryland-based Emergent BioSolutions inked another manufacturing agreement to support the development of a vaccine against COVID-19, the disease caused by the novel coronavirus.